Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
NOT YET RECRUITING
NCT07184385
PHASE3
A Study of Human Umbilical Cord Blood (REGENECYTE) Infusion in Patients With Post-COVID Condition
Sponsor: StemCyte, Inc.
View on ClinicalTrials.gov
Summary
REGENECYTE (HPC, Cord Blood) for treatment in patients with post-COVID.
Official title: A Multicenter, Double-blind, Randomized, Placebo-controlled, Two-arm Phase III Study to Assess the Efficacy of Human Umbilical Cord Blood (REGENECYTE) Infusion in Reducing Fatigue in Post-COVID Condition
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
60
Start Date
2026-03-31
Completion Date
2027-09-30
Last Updated
2025-09-23
Healthy Volunteers
No
Interventions
BIOLOGICAL
REGENECYTE
HPC, Cord Blood
BIOLOGICAL
Placebo
Normal Saline